Considering that the PD-L1/PD-1 axis constitutes a major therapeutic target in solid tumors and hematologic malignancies, our data provide significant insights into therapy resistance mechanisms and the development of immune adverse events. The gene discussed is PDCD1; the disease is hematologic disorder.